Table 1. Multiplication of M. leprae organisms in nude mice to determine minimal effective dose of BDQ administered orally active against M. leprae and the benefit of the combination of CFZ and BDQ.
| Treatmenta | Positive footpad/ total footpad | Range of AFB/positive footpads (mean log10 AFB/ footpad standard deviation on positive footpads) | p valueb |
|---|---|---|---|
| Untreated control | 10/10 | 7.79–8.67 (8.13±0.26) |
/ |
| RIF 10 mg/kg | 6/10 | 4.54–5.72 (NAc) |
0.08 |
| BDQ 0.10 mg/kg | 10/10 | 6.62–8.06 (7.39±0.50) |
1 |
| BDQ 0.33 mg/kg | 10/10 | 6.50–7.57 (7.02±0.40) |
1 |
| BDQ 1 mg/kg | 10/10 | 7.08–7.94 (7.56±0.32) |
1 |
| BDQ 3.3 mg/kg | 0/10 | NAc | 0.00001 |
| BDQ 25 mg/kg | 0/10 | NAc | 0.00001 |
| CFZ 20 mg/kg | 3/10 | 4.54 (NAc) |
0.003 |
| BDQ 0.10 mg/kg + CFZ 20 mg/kg | 2/10 | 4.54–5.15 (NAc) |
0.0007 |
| BDQ 0.33 mg/kg + CFZ 20 mg/kg | 1/10 | 5.54 (NAc) |
0.00009 |
a treatment was given by oral gavage 5 days a week for 24 weeks beginning one month after inoculation
b comparisons of the proportion of mice with positive footpads of each treated group versus untreated control (a p-value <0.005 was considered to be statistically significant when applying Bonferroni’s correction).
c not applicable